Island Pharmaceuticals Halts Trading Pending Ebola Trial Update
Key points
- Trading halt requested for Island Pharmaceuticals shares
- Halt pending announcement on Galidesivir use in Ebola trial
- Halt to remain until July 7 or announcement release
- Aimed at managing disclosure and maintaining market order
Full summary
Island Pharmaceuticals Limited (ASX: ILA) has requested a trading halt on its securities to be effective from the announcement date. The halt is requested pending an announcement regarding the use of Galidesivir in a clinical trial for Ebola in Africa. The trading halt will remain in effect until the earlier of the commencement of normal trading on July 7, 2026, or the release of the announcement. The company seeks the halt to manage its disclosure obligations and maintain an orderly market in its shares.
Summary generated by a large language model. Please interpret with care.